Nasal Human Abuse Potential of PTI-821

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

38 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-05-15

Study Completion Date

2017-12-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study will evaluate the human abuse liability of PTI-821 (oxycodone extended-release capsules) when administered nasally compared to crushed oxycodone IR tablets and crushed OxyContin tablets, also administered nasally.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study to Evaluate the Subjective Effects of PTI-801 in Non-Physically Dependent Subjects With a History of Drug Abuse

NCT00734461

Opioid-Related Disorders

COMPLETED PHASE2

A Comparison of How Likely it is That Different Tablets of Oxycodone Will be Broken up and Snorted by Adults Who Sometimes Take Drugs for Pleasure

NCT03765346

Substance Abuse

COMPLETED PHASE1

Evaluation of Intranasal Naltrexone and Naloxone

NCT03851731

Opioid-use Disorder

COMPLETED PHASE1

NT-814: Evaluation of Its Ability to Alter the Abuse Liability of Oxycodone in an Exploratory Clinical Study

NCT02692157

Opioid Use Disorder

WITHDRAWN PHASE1/PHASE2

The Potential of Oxytocin to Reduce Opioid Abuse Liability and Pain Among Older Adults

NCT05761860

Pain

RECRUITING EARLY_PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The nasal human abuse liability of PTI-821 will be compared to oxycodone IR using pharmacokinetic and pharmacodynamic assessments. A comparison to OxyContin will be dose using pharmacokinetic assessments.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Opioid Abuse Nondependent

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

4-way single-dose crossover with an exploratory 5th treatment arm

Primary Study Purpose

OTHER

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Double-blind, double-dummy

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PTI-821 Manipulated

oxycodone 40 mg capsule

Group Type EXPERIMENTAL

PTI-821 capsule Manipulated

Intervention Type DRUG

PTI-821 (oxycodone) 40 mg extended release capsule

Oxycodone

Oxycodone 40 mg IR tablet crushed

Group Type ACTIVE_COMPARATOR

Oxycodone

Intervention Type DRUG

Crushed oxycodone 40 mg immediate release tablet

OxyContin

Oxycodone ER 40 mg tablet crushed

Group Type ACTIVE_COMPARATOR

OxyContin

Intervention Type DRUG

Crushed OxyContin (oxycodone) extended-release 40 mg tablet

Placebo

Matching placebos for experimental and active comparator arms

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

Matching placebos for PTI-821 and oxycodone IR

PTI-821 Non-manipulated

Oxycodone 40 mg non-manipulated

Group Type EXPERIMENTAL

PTI-821 Non-manipulated

Intervention Type DRUG

PTI-821 (oxycodone) 40 mg capsule extended release capsule

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PTI-821 capsule Manipulated

PTI-821 (oxycodone) 40 mg extended release capsule

Intervention Type DRUG

PTI-821 Non-manipulated

PTI-821 (oxycodone) 40 mg capsule extended release capsule

Intervention Type DRUG

OxyContin

Crushed OxyContin (oxycodone) extended-release 40 mg tablet

Intervention Type DRUG

Placebo

Matching placebos for PTI-821 and oxycodone IR

Intervention Type OTHER

Oxycodone

Crushed oxycodone 40 mg immediate release tablet

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy male and/or female subjects between the ages of 18 and 55 years,
* Subject is a recreational opioid user who is NOT dependent on opioids
* Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and body weight \> 50 kg (110lbs).
* Evidence of a personally signed and dated informed consent document
* Subjects must be willing and able to comply with study procedures.
* Females who are physically incapable of childbearing, or practicing an acceptable method of birth control. Acceptable methods of birth control include surgical sterilization, hormonal contraceptives, or double-barrier methods (condom or diaphragm with a spermicidal agent or intrauterine device).

Exclusion Criteria

* Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).
* Diagnosis of substance and/or alcohol dependence (excluding caffeine and nicotine).
* Has participated in, is currently participating in, or is seeking treatment for substance- and/or alcohol-related disorders (excluding nicotine and caffeine).
* Has a positive urine drug screen (UDS) excluding tetrahydrocannabinol (THC) at Screening and the admission for Qualification Phase.
* Has a positive alcohol breath test at Screening or upon admission to the study center for the Qualification Phase.
* Has any history of a condition in which an opioid is contraindicated
* History of sleep apnea in the past 5 years that has not been resolved.
* Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject unsuitable for entry into this study.
* Positive test for Hepatitis B, Hepatitis C, or HIV at Screening.
* Allergy or history of hypersensitivity to naloxone hydrochloride (HCl), oxycodone HCl, other opioids, and/or lactose.
* Any condition possibly affecting drug absorption.
* Physical (eg, constricted or collapsed veins) or mental obstruction (ie, phobia) that would prevent serial blood sample collection.
* Clinically significant illness in the judgment of the investigator within 30 days before Screening.
* Treatment with an investigational drug within 30 days (or as determined by the local requirement, whichever is longer) or 5 half-lives preceding the first treatment during the Qualification Period (Visit 2), if longer than 30 days.
* Screening BP \> 140 mm Hg (systolic) or \> 90 mm Hg (diastolic) following at least 5 minutes of rest. If BP is \> 140 mm Hg (systolic) or \> 90 mm Hg (diastolic), the BP should be repeated two more times and the average of the three BP values should be used to determine the subject's eligibility.
* Pregnant females; breastfeeding females; males and females of childbearing potential who are unwilling or unable to use a highly effective method of contraception as outlined in this protocol for the duration of the study and for 28 days after the last dose of study medication. Urine pregnancy tests must be collected and confirmed negative prior to dosing upon admission.
* Is currently taking a drug for a medical condition or a nutraceutical that poses a safety risk when administered with an opioid, cannot be safely withdrawn at Screening for the duration of the study, and/or will adversely affect the PD and safety assessments required by the study. Examples include antihypertensive agents, drugs for seizures, and diabetes medications. Hormonal contraceptives (oral, injected, intrauterine, transdermal or implanted) are allowed in this study provided the subject remains on the same treatment throughout the entire study and has been using that hormonal contraceptive for an adequate period of time to ensure effectiveness. Limited use of non-prescription medications that are not believed to affect subject safety or the overall results of the study may be permitted on a case-by-case basis following approval by the investigator. As an exception, acetaminophen may be used at doses of 1 g/day.
* Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more within 30 days prior to dosing.
* Unwilling or unable to comply with the procedures described in this protocol.
* Unwilling to be searched (including personal effects) for illicit substances before admission to the study center.
* Subject is a heavy smoker (\> 20 cigarettes per day on average in the past 30 days prior to Screening), chews tobacco, uses nicotine-containing products (including nicotine transdermal patches), and/or is unable to abstain from smoking for at least 10 hours during any day.
* Current pending legal charges or currently on probation.
* Subjects who are investigational site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or subjects who are PTI employees directly involved in the conduct of the study.

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes